Adolor Corp (ADLR)

[surf1944]

8:33AM Adolor reports EPS in-line, beats on revs (ADLR) 1.83 : Reports Q2 (Jun) loss of $0.36 per share, in-line with the First Call consensus of ($0.36); revenues fell 66.3% year/year to $9.1 mln vs the $8.8 mln consensus. "We continue to see growth in important metrics for ENTEREG, including registrations and formulary approvals, and are now beginning to see this translate into increased utilization of our product. Further, we are pleased to note that the first independently conducted post-marketing case study of ENTEREG will be presented to the medical community by Dr. Timothy L. Beard at the Annual Meeting of the Northwest Society of Colon and Rectal Surgeons in early August. We expect other case studies to follow and believe that such 'real world' studies of ENTEREG should be useful in fostering physician awareness of the potential benefits ENTEREG may offer to bowel resection patients."